MGTX - NASDAQ
MeiraGTx Holdings plc
$9.39
+1.6%MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
At a Glance
Live SnapshotMeiraGTx Holdings plc Management Team
Dr. Stuart Naylor Ph.D.
Chief Development Officer
Compensation
$1,101,165
Dr. Alexandria Forbes Ph.D.
Chief Executive Officer, President & Director
Compensation
$3,056,403
Dr. Robert K. Zeldin M.D.
Chief Medical Officer
Compensation
$1,097,400
Mr. Richard Brian Giroux B.A.
Chief Operating Officer & Chief Financial Officer
Compensation
$2,874,700
Mr. Robert J. Wollin J.D.
General Counsel & Secretary
Dr. Michel Michaelides M.D.
Head of Clinical Ophthalmology
Dr. David Rubinstein Ph.D.
Senior Vice President of Business Development
Ms. Christine Elise Sheehy
Senior Vice President of Global Integration
Mr. Tim Randall
Senior Vice President of Risk & Internal Controls
MeiraGTx Holdings plc Insider Positioning
During the last 12 months, insiders have sold $3.05M worth of MGTX shares, with no buying activity reported.
3 Months
0
0.00
207.7K
1.86M
-1.9M
-$1.86M
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
71.5K
611.40K
-611K
-$611K
9-12 Months
0
0.00
71.5K
583.05K
-583K
-$583K
Top Buyers
No buying activity
Top Sellers
Forbes Alexandria
Director, Officer: President & Ceo
$1.81M
Giroux Richard
Officer: Cfo & Coo
$990K
Naylor Stuart
Officer: Chief Dev. Officer
$259K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $3.05M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
MGTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 27, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | December 23, 2022 | January 24, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 02, 2022 | June 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 10, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 21, 2020 | June 02, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 29, 2019 | June 19, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.